"Texas Oncology is an independent private practice with more than 500 physicians and 210 locations across the state. Meeting the oncology needs of Texans for more than 35 years, the practice includes Texas Center for Proton Therapy, Texas Breast Specialists, Texas Oncology Surgical Specialists, and Texas Center for Interventional Surgery. As a lead participant in US Oncology Research, Texas Oncology played a role in the development of more than 100 FDA-approved therapies."

During the past decade, Texas Oncology - South Austin Cancer Center conducted 21 clinical trials. In the 10-year time frame, 21 clinical trials started and 27 clinical trials were completed, i.e. on average, 128.6% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 20 clinical trials were completed. i.e. 400% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Texas Oncology - South Austin Cancer Center" #1 sponsor was "National Cancer Institute (NCI)" with 9 trials, followed by "Pfizer" with 5 trials sponsored, "Hoffmann-La Roche" with 3 trials sponsored, "NSABP Foundation Inc" with 3 trials sponsored and "Radiation Therapy Oncology Group" with 3 trials sponsored. Other sponsors include 19 different institutions and companies that sponsored additional 23 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Texas Oncology - South Austin Cancer Center" #1 collaborator was "National Cancer Institute (NCI)" with 13 trials as a collaborator, "NRG Oncology" with 8 trials as a collaborator, "Cancer and Leukemia Group B" with 2 trials as a collaborator, "Merck Sharp & Dohme LLC" with 2 trials as a collaborator and "NCIC Clinical Trials Group" with 2 trials as a collaborator. Other collaborators include 11 different institutions and companies that were collaborators in the rest 19 trials.

According to Clinical.Site data, the most researched conditions in "Texas Oncology - South Austin Cancer Center" are "Non-Small Cell Lung Cancer" (4 trials), "Ovarian Cancer" (4 trials), "Breast Cancer" (3 trials), "Breast Adenocarcinoma" (2 trials) and "Clear Cell Renal Cell Carcinoma" (2 trials). Many other conditions were trialed in "Texas Oncology - South Austin Cancer Center" in a lesser frequency.

Most popular intervention types in "Texas Oncology - South Austin Cancer Center" are "Drug" (41 trials), "Other" (15 trials), "Biological" (12 trials), "Radiation" (11 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (13 trials), "Carboplatin" (8 trials), "Paclitaxel" (8 trials), "Quality-of-Life Assessment" (8 trials) and "Bevacizumab" (5 trials). Other intervention names were less common.

The vast majority of trials in "Texas Oncology - South Austin Cancer Center" are 29 trials for "All" genders, 16 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Texas Oncology - South Austin Cancer Center". undefined are not yet recruiting, 4 are recruiting, 16 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 20 completed trials in Texas Oncology - South Austin Cancer Center, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Texas Oncology - South Austin Cancer Center, 2 "Phase 1" clinical trials were conducted, 19 "Phase 2" clinical trials and 28 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".